FDA Approval Insights: NALIRIFOX in Metastatic Pancreatic Cancer
Season 10, Episode 19, Mar 11, 2024, 06:00 PM
Share
Subscribe
Dr Wainberg discusses the FDA approval of first-line NALIRIFOX for patients with metastatic pancreatic adenocarcinoma, key data from NAPOLI 3, and the potential evolution of NALIRIFOX’s role in the treatment of patients with pancreatic cancer.